Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer"
Saved in:
| Main Authors: | Arun Kumar Goel, Sudarsan De |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2011-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2011;volume=32;issue=1;spage=43;epage=45;aulast=Goel |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01) -
Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01) -
Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
by: Yutaka Yamamoto, et al.
Published: (2018-01-01) -
Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids
by: Ahmed S. Mohamed, et al.
Published: (2025-03-01) -
The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)